X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SUN PHARMA JUBILANT LIFE SCIENCES/
SUN PHARMA
 
P/E (TTM) x 19.8 39.1 50.8% View Chart
P/BV x 4.8 3.0 161.0% View Chart
Dividend Yield % 0.4 0.8 49.2%  

Financials

 JUBILANT LIFE SCIENCES   SUN PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
SUN PHARMA
Mar-17
JUBILANT LIFE SCIENCES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs187842 22.2%   
Low Rs65572 11.4%   
Sales per share (Unadj.) Rs364.3131.6 276.8%  
Earnings per share (Unadj.) Rs6.832.7 20.9%  
Cash flow per share (Unadj.) Rs24.538.0 64.5%  
Dividends per share (Unadj.) Rs3.003.50 85.7%  
Dividend yield (eoy) %2.40.5 481.3%  
Book value per share (Unadj.) Rs164.9152.7 108.0%  
Shares outstanding (eoy) m159.282,399.26 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.4 6.4%   
Avg P/E ratio x18.421.6 85.1%  
P/CF ratio (eoy) x5.118.6 27.6%  
Price / Book Value ratio x0.84.6 16.5%  
Dividend payout %43.810.7 409.5%   
Avg Mkt Cap Rs m20,0611,696,877 1.2%   
No. of employees `0006.217.5 35.3%   
Total wages/salary Rs m11,05249,023 22.5%   
Avg. sales/employee Rs Th9,383.018,028.3 52.0%   
Avg. wages/employee Rs Th1,786.92,798.8 63.8%   
Avg. net profit/employee Rs Th176.34,479.5 3.9%   
INCOME DATA
Net Sales Rs m58,034315,784 18.4%  
Other income Rs m1916,232 3.1%   
Total revenues Rs m58,224322,016 18.1%   
Gross profit Rs m5,786100,893 5.7%  
Depreciation Rs m2,81212,648 22.2%   
Interest Rs m3,2373,998 81.0%   
Profit before tax Rs m-7290,479 -0.1%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m69612,116 5.7%   
Profit after tax Rs m1,09078,462 1.4%  
Gross profit margin %10.031.9 31.2%  
Effective tax rate %-965.913.4 -7,213.1%   
Net profit margin %1.924.8 7.6%  
BALANCE SHEET DATA
Current assets Rs m29,280329,537 8.9%   
Current liabilities Rs m38,912178,870 21.8%   
Net working cap to sales %-16.647.7 -34.8%  
Current ratio x0.81.8 40.8%  
Inventory Days Days8479 106.8%  
Debtors Days Days5183 60.9%  
Net fixed assets Rs m55,712204,766 27.2%   
Share capital Rs m1552,399 6.4%   
"Free" reserves Rs m20,968363,997 5.8%   
Net worth Rs m26,265366,397 7.2%   
Long term debt Rs m17,16914,361 119.6%   
Total assets Rs m88,606614,102 14.4%  
Interest coverage x1.023.6 4.1%   
Debt to equity ratio x0.70 1,667.8%  
Sales to assets ratio x0.70.5 127.4%   
Return on assets %4.913.4 36.4%  
Return on equity %4.221.4 19.4%  
Return on capital %11.624.8 46.6%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00444,118 49.9%   
Fx outflow Rs m11,74924,484 48.0%   
Net fx Rs m10,25519,634 52.2%   
CASH FLOW
From Operations Rs m8,02670,822 11.3%  
From Investments Rs m-1,744-42,216 4.1%  
From Financial Activity Rs m-4,447-22,854 19.5%  
Net Cashflow Rs m1,8346,107 30.0%  

Share Holding

Indian Promoters % 45.6 63.7 71.6%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.1 169.6%  
FIIs % 21.2 23.0 92.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 8.3 254.2%  
Shareholders   23,815 133,026 17.9%  
Pledged promoter(s) holding % 15.9 0.5 2,990.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  NATCO PHARMA  

Compare JUBILANT LIFE SCIENCES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day Flat; Auto Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a positive note.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


May 22, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 8-QTR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS